President & CEO of Endo Pharmaceuticals Holdings Inc. (ENDP, Financial) David Holveck buys 28,964 shares of ENDP on 03/10/2009 at an average price of $16.74 a share.
Endo Pharmaceuticals Holdings Inc. through its wholly owned subsidiaries Endo Pharmaceuticals Inc. and Endo Inc. is engaged in the research development sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain. Endo Pharmaceuticals Holdings Inc. has a market cap of $1.91 billion; its shares were traded at around $16.42 with a P/E ratio of 7 and P/S ratio of 1.5. Endo Pharmaceuticals Holdings Inc. had an annual average earning growth of 25.5% over the past 5 years.
ENDP is in the portfolios of Carl Icahn of Icahn Capital Management LP.
Recent Trades of Endo Pharmaceuticals Holdings Inc. by CEO:
Recent Trades of Endo Pharmaceuticals Holdings Inc. by Directors and Officers:
Endo Pharmaceuticals Holdings Inc. through its wholly owned subsidiaries Endo Pharmaceuticals Inc. and Endo Inc. is engaged in the research development sales and marketing of branded and generic prescription pharmaceuticals used primarily for the treatment and management of pain. Endo Pharmaceuticals Holdings Inc. has a market cap of $1.91 billion; its shares were traded at around $16.42 with a P/E ratio of 7 and P/S ratio of 1.5. Endo Pharmaceuticals Holdings Inc. had an annual average earning growth of 25.5% over the past 5 years.
ENDP is in the portfolios of Carl Icahn of Icahn Capital Management LP.
Recent Trades of Endo Pharmaceuticals Holdings Inc. by CEO:
- Buy: President & CEO David Holveck bought 28,964 shares of ENDP stock on 03/10/2009 at the average price of $16.74; the price of the stock has decreased by 1.91% since.
Recent Trades of Endo Pharmaceuticals Holdings Inc. by Directors and Officers:
- Sell: E. Shaw Valence Portfolios, D. sold 1,521,230 shares of ENDP stock on 03/09/2009 at the average price of $16.9; the price of the stock has decreased by 2.84% since.
